Interestingly, no difference in food intake was observed between wild-type mice treated with the dual incretin GLP-1/GIP coagonist and those treated with the tri-agonist despite the difference in weight loss, and this was found to be due to significantly higher ATP expenditure in tri-agonist-treated diet-induced obese mice
Like anything, if it sounds too good to be true, it probably is
Its something that people dont know about but should absolutely be aware of, because with these medications, the incidence is increasing. Online, some GLP-1 users are sharing experiences similar to Agos
Selectivity: Because Ipamorelin doesnt spike cortisol, it avoids a major compounding factor
In before-and-after comparisons, treated scars tend to become flatter and lighter more quickly